SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS; A HIGH NUMBER OF PATIENTS ACHIEVE DOPPLER REMISSION AFTER 24 WEEKS

被引：0
|
作者：
Hammer, H. B. [1 ]
Hansen, I. M. J. [2 ]
Jarvinen, P. [3 ]
Leirisalo-Repo, M. [4 ,5 ]
Ziegelasch, M. [6 ]
Agular, B. [7 ]
Terslev, L. [8 ]
机构：
[1] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[2] Svendborg Hosp, Dept Rheumatol, Svendborg, Denmark
[3] Kiljavan Laaketutkimus, Dept Rheumatol, Kiljavan, Finland
[4] Helsinki Univ Hosp, Dept Rheumatol, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Hosp, Dept Rheumatol, Linkoping, Sweden
[7] Roche, Dept Med, Copenhagen, Denmark
[8] Copenhagen Univ Hosp Glostrup, Ctr Rheumatol & Spinal Dis, Copenhagen, Denmark
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.3533
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0200
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [21] Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
    Soubrier, Martin
    Frayssac, Thomas
    Pereira, Bruno
    Couderc, Marion, Sr.
    Daron, Coline
    Dubost, Jean Jacques
    Malochet-Guinamand, Sandrine
    Tournadre, Anne
    Mathieu, Sylvain
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1000 - S1001
  • [22] ASSESSMENT OF SUBCLINICAL ATHEROSCLEROSIS (FLOW MEDIATED DILATATION AND ARTERIAL STIFFNESS) AFTER 24 WEEKS OF TOCILIZUMAB THERAPY IN 22 PATIENTS WITH RHEUMATOID ARTHRITIS
    Soubrier, M.
    Verny, M. -A.
    Pereira, B.
    Frayssac, T.
    Couderc, M.
    Malochet-Guinamand, S.
    Tournadre, A.
    Mathieu, S.
    Dubost, J. -J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 649 - 649
  • [23] Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
    Uda, Hiroshi
    Shigematsu, Koji
    Ishizaki, Yoshitaka
    Saiki, Osamu
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial
    Sanmarti, Raimon
    Veale, Douglas J.
    Martin-Mola, Emilio
    Escudero-Contreras, Alejandro
    Gonzalez, Carlos
    Ercole, Liliana
    Alonso, Rocio
    Fonseca, Joao E.
    Alcaniz, Cristina
    Maria Alvaro-Gracia, Jose
    Balsa, Alejandro
    Luis de Pablos, Jose
    Diaz Miguel, Consuelo
    Manuel Rodriguez, Jose
    Alves, Jose
    Aurrecoechea, Elena
    Calvo, Jaime
    Belzunegui, Joaquin
    Blanco, Francisco
    Caliz, Rafael
    Calvo, Javier
    Roman Ivorra, Jose
    Canhao, Helena
    Santos, Helena
    Chamizo, Eugenio
    del Pino, Javier
    Delgado, Concepcion
    Diaz, Cesar
    Fernandez Nebro, Antonio
    Fraser, Alexander
    Gomez, Antonio
    Hernandez, Blanca
    Navarro, Federico
    Pov-Marras, Juan
    Moreno, Juan
    Perez Venegas, Jose
    Pombo, Manuel
    Riera, Elena
    Rosas, Antonio
    Ryan, John
    Santos, Jose
    Santos, Maria
    Tornero, Jesus
    Victor Tovar, Juan
    Ucar, Eduardo
    Vasconcelos, Carlos
    Veiga, Raul
    Vela, Paloma
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (10) : 1616 - 1625
  • [25] Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis.
    Saiki, Osamu
    Uda, Hiroshi
    Shigematsu, Koji
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S219 - S219
  • [26] IDENTIFICATION OF SYNOVITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL REMISSION DURING THERAPY WITH TOCILIZUMAB
    Panasyuk, E.
    Smirnov, A.
    Fedorenko, E.
    Gavva, T.
    Gubar, E.
    Loginova, E.
    Lukina, G.
    Luchikhina, E.
    Tsvetkova, E.
    Avdeeva, A.
    Alexandrova, E.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 508 - 509
  • [27] Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience
    Epis, Oscar
    Casu, Cinzia
    Belloli, Laura
    Schito, Emanuela
    Filippini, Davide
    Muscara, Marina
    Bruschi, Eleonora
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (09) : 1569 - 1570
  • [28] Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience
    Oscar Epis
    Cinzia Casu
    Laura Belloli
    Emanuela Schito
    Davide Filippini
    Marina Muscarà
    Eleonora Bruschi
    Rheumatology International, 2015, 35 : 1569 - 1570
  • [29] MOLECULAR SIGNATURE IN SUSTAINED CLINICAL REMISSION INDUCED BY TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kajio, N.
    Suzuki, K.
    Matsumoto, K.
    Iijima, H.
    Nakamura, S.
    Ishizawa, Y.
    Inamo, J.
    Takeshita, M.
    Yoshimoto, K.
    Kaneko, Y.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 526 - 526
  • [30] Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naive Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 24 Weeks Of Follow-Up
    Tsuji, Soichiro
    Yura, Akiko
    Katayama, Michihito
    Teshigawara, Satoru
    Yoshimura, Maiko
    Tanaka, Eriko
    Harada, Yoshinori
    Katada, Yoshinori
    Matsushita, Masato
    Ohshima, Shiro
    Hashimoto, Jun
    Saeki, Yukihiko
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1011 - S1011
12345